Integrated Synthesis and Testing of Substituted Xanthine Based DPP4 Inhibitors: Application to Drug Discovery.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Chemical Biology

Background:

• Dipeptidyl peptidase 4 (DPP4) inhibitors are crucial for managing type 2 diabetes.
• Traditional drug discovery involves lengthy iterative cycles of synthesis and testing.
• Efficient methods for rapid generation of structure-activity relationships (SAR) are needed.

Purpose of the Study:

• To develop and validate a novel integrated platform for the automated synthesis and biological assay of DPP4 antagonists.
• To demonstrate the platform's capability for rapid iterative SAR generation.

Main Methods:

• An integrated discovery platform was employed for automated design, synthesis, purification, quantitation, dilution, and bioassay.
• The platform's performance was validated against known DPP4 inhibitors.
• Iterative synthesis and biological assay cycles were performed.

Main Results:

• The integrated platform successfully synthesized and biologically assayed xanthine-derived DPP4 antagonists.
• Excellent correlation was observed between platform data and traditional medicinal chemistry data.
• Each synthesis-to-bioassay loop was completed in two hours, enabling rapid SAR exploration.

Conclusions:

• The novel integrated platform provides a highly efficient and automated approach for DPP4 antagonist discovery.
• This system significantly accelerates the generation of structure-activity relationships, facilitating faster lead optimization.
• The platform demonstrates a powerful tool for advancing medicinal chemistry and drug discovery efforts.